Dermatological
The US biotech is paying $250m upfront to the Danish group in what is the second STAT6 deal secured in the past three weeks.
The head of Chugai's new $200m venture capital fund talks to Scrip about its investment priorities.
The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.
Japanese major highlights at R&D Day key late-stage pipeline assets set to be filed for approval over the next few years, which it says have a combined peak sales potential of $10-20bn, and which could help it weather the expiry of current blockbuster Entyvio.
Nemluvio is the first IL-31 inhibitor approved by the US FDA for atopic dermatitis and will compete with Sanofi/Regeneron’s Dupixent and other, newer IL-13 inhibitors.
Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.
CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.
The US healthcare giant says that icotrokinra could provide an “industry-leading combination of significant skin clearance with demonstrated tolerability in a once-daily pill" after succeeding in late-stage trials.
Incyte is looking to expand in dermatology, but two products at the center of its Escient buyout earlier this year have run into some trouble.
The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.
Rocatinlimab met its Phase III endpoints with results that appear uncompetitive with AD market leader Dupixent, while Uplizna may offer a compelling twice-yearly gMG treatment option.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Organon will pay $175m up front for Roivant subsidiary Dermavant and its topical therapy for psoriasis Vtama. The acquirer is betting on growth from adding atopic dermatitis to Vtama’s label.
New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.
The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.
TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.
The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
After a quiet July, August and September are shaping up to be busy on the approvals front. Already this month, the US FDA has approved Adaptimmune’s Teclera for synovial sarcoma, Phathom’s Voquezna for gastro-esophageal reflux disease and Servier’s Voranigo for gliomas. Here, Scrip takes a look at ten other approvals for novel products in the offing for the third quarter.
The JAK inhibitor cream for hand eczema will serve a large market in Europe and help the Danish dermatology specialist expand its strong position in dermatology.